PHARMACEUTICAL RESEARCH

药学研究共享资源 David Adams，Ph.D.，Ashley Morris-Engemann，Pharm.D.，联席董事 药物研究共享资源由研究化疗服务和Cancex组成 临床药理实验室，提供广泛的服务，支持临床的开展 血液学/本体论研究。研究化疗服务(ICS)适用于所有癌症中心 调查人员，以维护药物可接受性记录和调查药品库存为目的 符合FDA和CTEP指南。此外，该资源还提供设计咨询、专业人员培训和 临床研究研究的实施服务。临床药理实验室(CPL)的主要关注点是 抗癌药物和重组蛋白在体内的药代动力学和药效学研究 癌症的实验性治疗。此资源也可用于内源性细胞因子浓度的分析 在研究治疗期间。该实验室的主要目标之一是确定反应和 毒性和实施方法，以减少患者间药物暴露的可变性。劳顾会提供两项咨询服务 以及抗癌化合物和重组蛋白的临床药代动力学研究的分析服务。 其中包括：协助试验设计、最佳抽样技术、样本处理和稳定性、定量 药物和代谢物浓度的测量(通过高效液相色谱、原子吸收分光光度法、气体分析法 计算个体和群体的药代动力学 通过复杂的计算机建模程序进行参数和药物计量评估。此资源具有 保持癌症中心研究人员的高使用率，包括实验治疗学的研究人员 项目，乳房和卵巢骨髓放射和 本体论、移植、神经肿瘤学、肿瘤学 热疗和癌症免疫生物学项目。在上一财年，100%的资源利用率是 为同行评议的调查人员生成。

PHARMACEUTICAL RESEARCH SHARED RESOURCE David Adams, Ph.D., Ashley Morris-Engemann, Pharm.D., Co-Directors The Pharmaceutical Research Shared Resource consists of an lnvestigational Chemotherapy Service and a Cancex Clinical Pharmacology Laboratory, provides a broad range of services to support the conduct of clinical hematology/ontology research. The Investigational Chemotherapy Service (ICS) is available to all Cancer Center investigators for the purpose of maintaining drug accotmtability records and investigafional drug inventories according to FDA and CTEP guidelines. In addition, this resource provides design consultation, professional staff education, and implementation services for clinical research studies. The primary focus of the Clinical Pharmacology Lab (CPL) is to investigate the pharmacokinetics and pharmacodynamics of anticancer drugs and recombinant proteins used in the experimental therapy of cancer. This resource is also available for analysis of endogenous cytokine concentrations during investigational therapy. One of the major goals of the laboratory is to identify predictors of response and toxicity and implement methods to reduce inter-patient variability of drug exposure. The lab provides both consultative and analytic services regarding clinical pharmacokinetie studies of anticancer compounds and recombinant proteins. These include: aid with trial design, optimal sampling techniques, sample handling and stability, quantitative measurement of drug and metabolite concentrations (via HPLC, atomic absorption spcetrophotometry, gas chromatography/mass spectrophotometry, or ELISA), calculation of individual and population pharmacokinetic parameters and pharmacometric evaluation via sophisticated computer modeling programs. This resource has maintained a high level of usage by Cancer Center investigators including those from the Experimental Therapeutics Program, Breast and Ovarian Bone Marrow Radiation and Ontology, Transplantation, Neuro-Oncology, Oncology Hyperthermia, and Cancer Immtmobiology Programs. During the last fiscal year, 100% of the resource utilization was generated for peer-reviewed investigators.